Skip to main content

A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases

Part of the Advances in Experimental Medicine and Biology book series (PMISB,volume 1291)

Abstract

Gastrointestinal (GI) diseases are highly prevalent worldwide, with considerable morbidity and mortality. Curcumin has been used for many years as a plant-derived product for the management of various conditions such as abdominal pain and poor digestion. This systematic review was undertaken with the aim of investigating the effect of curcumin or turmeric supplementation on GI diseases. A comprehensive systematic search was conducted in PubMed, Scopus, Web of Science and Google Scholar up to March 2020 to identify clinical trials assessing the effect of curcumin/turmeric alone or in combination with other herbs or nutrients on GI diseases. Twenty-one studies comprising 1478 GI patients were included in the study. Four out of seven studies showed a beneficial effect of curcumin/turmeric supplementation on irritable bowel syndrome (IBS) and six out of seven showed positive effects of these herbs on ulcerative colitis. Two out of four studies highlighted the potential role of curcumin/turmeric in eradication of H. pylori infection. Both studies conducted on peptic ulcer disease and two out of four studies performed on Crohn’s disease demonstrated positive effects of curcumin/turmeric supplementation. One study showed curcumin supplementation had no effect on familial adenomatous polyposis. However, in another study, curcumin had favorable effects on proctosigmoiditis. Nine studies reported some minor adverse effects. The results of this systematic review suggest a beneficial effect of curcumin/turmeric supplementation on the management of GI diseases. More randomized clinical controlled trials are needed to confirm these results.

Keywords

  • Gastrointestinal diseases
  • Curcumin
  • Turmeric
  • IBS
  • Ulcerative colitis

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-56153-6_18
  • Chapter length: 32 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   169.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-56153-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   219.99
Price excludes VAT (USA)
Fig. 18.1

References

  1. Chan JSH, Chao ACW, Cheung VCH, Wong SSK, Tang W, Wu JCY et al (2019) Gastrointestinal disease burden and mortality: a public hospital-based study from 2005 to 2014. J Gastroenterol Hepatol 34(1):124–131

    PubMed  CrossRef  Google Scholar 

  2. Langmead L, Rampton D (2001) Herbal treatment in gastrointestinal and liver disease—benefits and dangers. Aliment Pharmacol Ther 15(9):1239–1252

    CAS  PubMed  CrossRef  Google Scholar 

  3. Bundy R, Walker AF, Middleton RW, Booth J (2004) Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 10(6):1015–1018

    PubMed  CrossRef  Google Scholar 

  4. Brinkhaus B, Hentschel C, Keudell CV, Schindler G, Lindner M, Stützer H et al (2005) Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 40(8):936–943

    PubMed  CrossRef  Google Scholar 

  5. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS (2018) A meta-analysis of the clinical use of curcumin for irritable bowel syndrome (IBS). J Clin Med 7(10):E298. https://doi.org/10.3390/jcm7100298

    CAS  CrossRef  PubMed  Google Scholar 

  6. Soleimani V, Sahebkar A, Hosseinzadeh H (2018) Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytother Res 32(6):985–995. https://doi.org/10.1002/ptr.6054. Epub 2018 Feb 26. PMID: 29480523

  7. Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A (2018) Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? J Cell Physiol 233(2):830–848

    CAS  PubMed  CrossRef  Google Scholar 

  8. Iranshahi M, Sahebkar A, Takasaki M, Konoshima T, Tokuda H (2009) Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur J Cancer Prev 18(5):412–415

    CAS  PubMed  CrossRef  Google Scholar 

  9. Khonche A, Biglarian O, Panahi Y, Valizadegan G, Soflaei S, Ghamarchehreh M et al (2016) Adjunctive therapy with curcumin for peptic ulcer: a randomized controlled trial. Drug Res 66(8):444–448

    CAS  CrossRef  Google Scholar 

  10. Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A (2019) Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr 59(1):89–101

    CAS  PubMed  CrossRef  Google Scholar 

  11. Hasanzadeh S, Read MI, Bland AR, Majeed M, Jamialahmadi T, Sahebkar A (2020) Curcumin: an inflammasome silencer. Pharmacol Res 159:104921. https://doi.org/10.1016/j.phrs.2020.104921. Epub 2020 May 25. PMID: 32464325.

  12. Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ (2020) The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res 34(5):1123–1133

    CAS  PubMed  CrossRef  Google Scholar 

  13. Momtazi AA, Sahebkar A (2016) Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr Pharm Des 22(28):4386–4397

    CAS  PubMed  CrossRef  Google Scholar 

  14. Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A (2016) Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther 20(4):335–345

    CAS  PubMed  Google Scholar 

  15. Teymouri M, Pirro M, Johnston TP, Sahebkar A (2017) Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. BioFactors 43(3):331–346.

    Google Scholar 

  16. Talebi S, Bagherniya M, Atkin SL, Askari G, Orafai HM et al (2020) The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis 19:1–21

    CrossRef  Google Scholar 

  17. Bagherniya M, Nobili V, Blesso CN, Sahebkar A (2018) Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: a clinical review. Pharmacol Res 130:213–240

    CAS  CrossRef  PubMed  Google Scholar 

  18. Bagherniya M, Johnston T, Sahebkar A (2020) Regulation of apolipoprotein B by natural products and nutraceuticals: a comprehensive review. Curr Med Chem. https://doi.org/10.2174/0929867327666200427092114. [Epub ahead of print]

  19. Rezaee R, Momtazi AA, Monemi A, Sahebkar A (2017) Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res 117:218–227

    CAS  PubMed  CrossRef  Google Scholar 

  20. Rajasekaran SA (2011) Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2(1):1

    PubMed  PubMed Central  CrossRef  Google Scholar 

  21. Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW et al (eds) (1998) The complete German commission E monographs. Therapeutic guide to herbal medicines. American Botanical Council, Austin, TX. ISBN-10: 096555550X

    Google Scholar 

  22. Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O et al (2015) Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 13(8):1444–1449. e1441

    CAS  PubMed  CrossRef  Google Scholar 

  23. Portincasa P, Bonfrate L, Scribano ML, Kohn A, Caporaso N, Festi D et al (2016) Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointestin Liver Dis 25(2):151–157

    PubMed  CrossRef  Google Scholar 

  24. Lior O, Sklerovsy-Benjaminov F, Lish I, Konokoff F, Naftali T (2019) Treatment of irritable bowel syndrome with a combination of curcumin, Green Tea and Selenomethionine has a positive effect on satisfaction with Bowel habits. J Biosci Med 7(5):170–179

    CAS  Google Scholar 

  25. Lauche R, Kumar S, Kreppenhofer J, Lüdtke R, Rampp T, Dobos G et al (2014) Efficacy and safety of ayurvedic herbs in diarrhea-predominant irritable Bowel syndrome—a randomized controlled cross-over trial. J Altern Complement Med 20(5):A81–A81

    Google Scholar 

  26. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269

    PubMed  CrossRef  Google Scholar 

  27. Moher D, Cook D, Jadad A, Tugwell P, Moher M, Jones A et al. (1999) Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 3(12):i–iv., 1–98

    Google Scholar 

  28. Di Ciaula A, Portincasa P, Maes N, Albert A (2018) Efficacy of bio-optimized extracts of turmeric and essential fennel oil on the quality of life in patients with irritable Bowel syndrome. Ann Gastroenterol 31(6):685–691

    PubMed  PubMed Central  Google Scholar 

  29. Shapira S, Leshno A, Katz D, Maharshak N, Hevroni G, Jean-David M et al (2018) Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis. Ther Adv Gastroenterol 11:1756283X17741864. https://doi.org/10.1177/1756283X17741864

    CrossRef  Google Scholar 

  30. Alt F, Chong PW, Teng E, Uebelhack R (2017) Evaluation of benefit and tolerability of IQP-CL-101 (xanthofen) in the symptomatic improvement of irritable bowel syndrome: a double-blinded, randomised, placebo-controlled clinical trial. Phytother Res 31(7):1056–1062

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  31. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A et al (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4(12):1502–1506

    CAS  PubMed  CrossRef  Google Scholar 

  32. Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P et al (2014) Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—a randomized, placebo-controlled, pilot study. J Crohns Colitis 8(3):208–214

    PubMed  CrossRef  Google Scholar 

  33. Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S et al (2017) Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther 8(2):147–154

    PubMed  PubMed Central  CrossRef  Google Scholar 

  34. Abbas SH, Abdulridha MK, Najeb AA (2017) Potential benefit of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease. Asian J Pharm Clin Res 10(5):313–317

    CAS  CrossRef  Google Scholar 

  35. Judaki A, Rahmani A, Feizi J, Asadollahi K, Hafezi Ahmadi MR (2017) Curcumin in combination with triple therapy regimes ameliorates oxidative stress and histopathologic changes in chronic gastritis-associated helicobacter pylori infection. Arq Gastroenterol 54(3):177–182

    PubMed  CrossRef  Google Scholar 

  36. Masoodi M, Mahdiabadi MA, Mokhtare M, Agah S, Kashani AH, Rezadoost AM et al (2018) The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self-reported well-being: a randomized double-blind controlled trial. J Cell Biochem 119(11):9552–9559

    CAS  PubMed  CrossRef  Google Scholar 

  37. Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J (2010) Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int Immunopharmacol 10(7):815–818

    CAS  PubMed  CrossRef  Google Scholar 

  38. Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50(11):2191–2193

    PubMed  CrossRef  Google Scholar 

  39. Cruz-Correa M, Hylind LM, Marrero JH, Zahurak ML, Murray-Stewart T, Casero RA Jr et al (2018) Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 155(3):668–673

    CAS  PubMed  CrossRef  Google Scholar 

  40. Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M et al (2019) Oral curcumin no more effective than placebo in preventing recurrence of Crohn's disease after surgery in a randomized controlled trial. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2019.08.041. pii: S1542-3565(19)30916-4 [Epub ahead of print]

  41. Chandan S, Mohan BP, Chandan OC, Ahmad R, Challa A, Tummala H et al (2020) Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. Ann Gastroenterol 33(1):53–58

    PubMed  Google Scholar 

  42. Lubbad A, Oriowo M, Khan I (2009) Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322(1–2):127–135

    CAS  PubMed  CrossRef  Google Scholar 

  43. Yu Y, Wu S, Li J, Wang R, Xie X, Yu X et al (2015) The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis 30(1):47–55

    CAS  PubMed  CrossRef  Google Scholar 

  44. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS (2019) Systematic review with meta-analysis: The association between post-traumatic stress disorder and irritable bowel syndrome. J Gastroenterol Hepatol 34(1):68–73

    PubMed  CrossRef  Google Scholar 

  45. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH et al (2006) Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163(9):1630–1633

    PubMed  CrossRef  Google Scholar 

  46. Xu Y, Ku B, Tie L, Yao H, Jiang W, Ma X et al (2006) Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 1122(1):56–64

    CAS  PubMed  CrossRef  Google Scholar 

  47. Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57(1):1–7

    CAS  PubMed  CrossRef  Google Scholar 

  48. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM et al (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7(7):1894–1900

    CAS  PubMed  Google Scholar 

  49. Feng W, Wang H, Zhang P, Gao C, Tao J, Ge Z et al (2017) Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta 1861(7):1801–1812

    CAS  CrossRef  Google Scholar 

  50. Wang J, Ghosh SS, Ghosh S (2017) Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions. Am J Physiol Cell Physiol 312(4):C438–C445

    PubMed  PubMed Central  CrossRef  Google Scholar 

  51. Sahebkar A, Cicero AF, Simental-Mendía LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 107:234–242

    CAS  PubMed  CrossRef  Google Scholar 

  52. Shakeri A, Panahi Y, Johnston TP, Sahebkar A (2019) Biological properties of metal complexes of curcumin. BioFactors 45(3):304–317

    CAS  PubMed  CrossRef  Google Scholar 

  53. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB et al (2009) Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 53(4):1592–1597

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

  54. Kundu P, De R, Pal I, Mukhopadhyay AK, Saha DR, Swarnakar S (2011) Curcumin alleviates matrix metalloproteinase-3 and-9 activities during eradication of Helicobacter pylori infection in cultured cells and mice. PLoS One 6(1):e16306. https://doi.org/10.1371/journal.pone.0016306

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  55. Santos AM, Lopes T, Oleastro M, Gato IV, Floch P, Benejat L et al (2015) Curcumin inhibits gastric inflammation induced by Helicobacter pylori infection in a mouse model. Nutrients 7(1):306–320

    PubMed  PubMed Central  CrossRef  CAS  Google Scholar 

  56. Münzenmaier A, Lange C, Glocker E, Covacci A, Moran A, Bereswill S et al (1997) A secreted/shed product of Helicobacter pylori activates transcription factor nuclear factor-kappa B. J Immunol 159(12):6140–6147

    PubMed  Google Scholar 

  57. Midura-Kiela MT, Radhakrishnan VM, Larmonier CB, Laubitz D, Ghishan FK, Kiela PR (2 012) Curcumin inhibits interferon-γ signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 302(1):G85–G96

    Google Scholar 

  58. Larmonier CB, Midura-Kiela M, Ramalingam R, Laubitz D, Janikashvili N, Larmonier N et al (2011) Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 17(2):503–515

    CAS  PubMed  CrossRef  Google Scholar 

  59. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T et al (2002) Curcumin prevents and ameliorates trinitrobenzene sulfonic acid–induced colitis in mice. Gastroenterology 123(6):1912–1922

    CAS  PubMed  CrossRef  Google Scholar 

  60. Cooney JM, Barnett MP, Dommels YE, Brewster D, Butts CA, McNabb WC et al (2016) A combined omics approach to evaluate the effects of dietary curcumin on colon inflammation in the Mdr1a−/− mouse model of inflammatory bowel disease. J Nutr Biochem 27:181–192

    CAS  PubMed  CrossRef  Google Scholar 

  61. McConnell R (1976) Familial polyposis Coli. family studies, histopathology, differential diagnosis, and results of treatment. J Med Genet 13(5):415–416

    PubMed Central  CrossRef  Google Scholar 

  62. McFadden R-MT, Larmonier CB, Shehab KW, Midura-Kiela M, Ramalingam R, Harrison CA et al (2015) The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis 21(11):2483–2494

    PubMed  CrossRef  Google Scholar 

  63. Dey N, Wagner VE, Blanton LV, Cheng J, Fontana L, Haque R et al (2015) Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell 163(1):95–107

    CAS  PubMed  PubMed Central  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Atefi, M., Darand, M., Entezari, M.H., Jamialahmadi, T., Bagherniya, M., Sahebkar, A. (2021). A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases. In: Guest, P.C. (eds) Studies on Biomarkers and New Targets in Aging Research in Iran. Advances in Experimental Medicine and Biology(), vol 1291. Springer, Cham. https://doi.org/10.1007/978-3-030-56153-6_18

Download citation